Exchange Traded Concepts LLC Trims Position in Omnicell, Inc. $OMCL

Exchange Traded Concepts LLC decreased its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 54.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,308 shares of the company’s stock after selling 20,520 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Omnicell were worth $527,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Graham Capital Management L.P. raised its position in Omnicell by 76.9% during the 1st quarter. Graham Capital Management L.P. now owns 65,638 shares of the company’s stock valued at $2,295,000 after purchasing an additional 28,536 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of Omnicell by 56.8% in the first quarter. Cubist Systematic Strategies LLC now owns 274,489 shares of the company’s stock valued at $9,596,000 after acquiring an additional 99,406 shares in the last quarter. EP Wealth Advisors LLC purchased a new stake in Omnicell in the first quarter worth about $245,000. Perbak Capital Partners LLP purchased a new stake in Omnicell in the first quarter worth about $347,000. Finally, AQR Capital Management LLC grew its holdings in Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock worth $627,000 after acquiring an additional 5,311 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a research report on Wednesday, October 8th. Zacks Research lowered Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. Finally, Benchmark lifted their price target on Omnicell from $45.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $43.00.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $45.92 on Wednesday. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $47.69. The company has a market cap of $2.06 billion, a PE ratio of 106.79, a P/E/G ratio of 5.05 and a beta of 0.83. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.21 and a current ratio of 1.44. The business has a 50-day simple moving average of $38.48 and a two-hundred day simple moving average of $33.26.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.